Advertisement
Canada markets open in 3 hours 36 minutes
  • S&P/TSX

    24,822.54
    +132.04 (+0.53%)
     
  • S&P 500

    5,864.67
    +23.20 (+0.40%)
     
  • DOW

    43,275.91
    +36.81 (+0.09%)
     
  • CAD/USD

    0.7236
    -0.0011 (-0.15%)
     
  • CRUDE OIL

    70.25
    +1.03 (+1.49%)
     
  • Bitcoin CAD

    94,325.30
    -204.55 (-0.22%)
     
  • XRP CAD

    0.76
    +0.02 (+2.39%)
     
  • GOLD FUTURES

    2,751.50
    +21.50 (+0.79%)
     
  • RUSSELL 2000

    2,276.09
    -4.76 (-0.21%)
     
  • 10-Yr Bond

    4.0730
    -0.0230 (-0.56%)
     
  • NASDAQ futures

    20,426.75
    -56.75 (-0.28%)
     
  • VOLATILITY

    18.87
    +0.84 (+4.66%)
     
  • FTSE

    8,357.30
    -0.95 (-0.01%)
     
  • NIKKEI 225

    38,954.60
    -27.15 (-0.07%)
     
  • CAD/EUR

    0.6668
    +0.0002 (+0.03%)
     

Aurinia: Q2 Earnings Snapshot

EDMONTON, Alberta (AP) — EDMONTON, Alberta (AP) — Aurinia Pharmaceuticals Inc. (AUPH) on Thursday reported second-quarter net income of $722,000, after reporting a loss in the same period a year earlier.

The Edmonton, Alberta-based company said it had profit of 1 cent per share. Earnings, adjusted for restructuring costs, were 2 cents per share.

The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 1 cent per share.

The biotechnology company posted revenue of $57.2 million in the period, also topping Street forecasts. Four analysts surveyed by Zacks expected $54.9 million.

Aurinia shares have dropped 34% since the beginning of the year. The stock has declined 49% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AUPH at https://www.zacks.com/ap/AUPH